Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 15/20 | 0.62 |
| ▸ | CA2 | P00918 | 15/20 | 0.62 |
| ▸ | CA12 | O43570 | 12/20 | 0.62 |
| ▸ | CA9 | Q16790 | 12/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | CA7 | P43166 | 3/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | CA4 | P22748 | 1/20 | 0.53 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5659088 | 0.85 | TGM2 (0.51) | CA1CA2CA12CA9 | |
| SCHEMBL3969793 | 0.77 | NPC1 (0.55) | CA1CA2CA12CA9KMT2A | |
| SCHEMBL3973745 | 0.77 | ALDH1A1 (0.55) | CA1CA2CA12CA9KMT2A | |
| SCHEMBL3723958 | 0.77 | NAPRT (0.52) | KMT2A | |
| SCHEMBL1517568 | 0.77 | KMT2A (0.66) | CA1CA2CA12CA9KMT2A | |
| Acetylsulfanilamide SCHEMBL359721 | 0.77 | CA1 (1.00) | CA1CA2CA12CA9KMT2A | |
| SCHEMBL28499329 | 0.76 | KMT2A (1.00) | CA1CA2CA12CA9KMT2A | |
| Bicarbonate SCHEMBL5658794 | 0.76 | KMT2A (0.65) | CA1CA2CA12CA9KMT2A | |
| Acetylsulfanilamide SCHEMBL8043497 | 0.75 | CA1 (0.96) | CA1CA2CA12CA9KMT2A | |
| Acetylsulfanilamide SCHEMBL8190989 | 0.75 | CA1 (0.96) | CA1CA2CA12CA9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7279473-B2 | Pyrazolopyridazine derivatives | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-09 | — | — | US | disclosed |
| EP-1463730-B1 | PYRAZOLOPYRIDAZINE DERIVATIVES | SMITHKLINE BEECHAM CORP (US) | 2006-04-19 | — | — | EP | disclosed |
| US-20050090507-A1 | Pyrazolopyridazine derivatves | SMITHKLINE BEECHAM CORPORATION | 2005-04-28 | — | — | US | disclosed |
| EP-1463730-A1 | PYRAZOLOPARIDAZINE DERIVATIVES | SmithKline Beecham Corporation (US) | 2004-10-06 | — | — | EP | disclosed |
| WO-2003051886-A1 | PYRAZOLOPYRIDAZINE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090507-A1 | Pyrazolopyridazine derivatves | CDK4, CDK3, CDK8 | CA1 4590/4885CA2 3895/4885CA12 4133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.